Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bulkamid for Recurrent SUI After Suburethral Sling Revision: Single-Center Study.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Comparison of Pediatric Demyelinating Diseases using Axonal and Myelin-Sensitive MRI.

AJNR. American journal of neuroradiology·2026
Same author

Recent Progress on Selenium Nanoparticles: Synthesis and Neuroprotective Effects for the Treatment of Alzheimer's Disease.

Molecular neurobiology·2026
Same author

DNA methylation signatures from peripheral blood revealed epigenetic alterations in Fanconi anemia.

Human genetics·2026
Same author

Gender Disparities in Procedural Management of Hunner Lesion Interstitial Cystitis.

Neurourology and urodynamics·2026
Same author

Communication when bone and joint infection in children is suspected : a qualitative study of patients, families, and health professionals.

Bone & joint open·2026
Same journal

Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.

Therapeutic advances in neurological disorders·2026
Same journal

Clinical, imaging, and immunotherapeutic features in MOGAD: a retrospective real-world cohort in Northern China.

Therapeutic advances in neurological disorders·2026
Same journal

Narcolepsy with co-occurring epilepsy: diagnostic pitfalls and management strategy.

Therapeutic advances in neurological disorders·2026
Same journal

Paradoxical myocardial infarction risk with dual antiplatelet therapy in East Asian ischaemic stroke: a nationwide real-world cohort study and pharmacogenomic risk prediction model.

Therapeutic advances in neurological disorders·2026
Same journal

Residual early neurological deterioration following dual antiplatelet in stroke: post hoc analysis of the ATAMIS trial.

Therapeutic advances in neurological disorders·2026
Same journal

Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers.

Therapeutic advances in neurological disorders·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Symptomatic therapy in multiple sclerosis.

Teresa C Frohman1, Wanda Castro, Anjali Shah

  • 1Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.

Therapeutic Advances in Neurological Disorders
|June 23, 2011
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) is a common disabling neurological disease in young adults. Effective MS management requires disease-modifying therapies and comprehensive multidisciplinary care focused on quality of life and function.

Keywords:
fatiguemultiple sclerosisneurogenic bowel and bladderspasticitysymptomatic therapyvisual symptoms

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Related Experiment Videos

Last Updated: May 31, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Area of Science:

  • Neurology
  • Neuroimmunology
  • Rehabilitation Medicine

Background:

  • Multiple sclerosis (MS) is the leading cause of neurological disability among young adults.
  • The disease significantly impacts patient quality of life and functional independence.

Purpose of the Study:

  • To emphasize the necessity of a holistic approach in managing multiple sclerosis.
  • To highlight the importance of integrating disease-modifying therapies with comprehensive care strategies.

Main Methods:

  • Literature review on current multiple sclerosis treatment paradigms.
  • Analysis of multidisciplinary care models and their impact on patient outcomes.
  • Synthesis of evidence supporting integrated therapeutic strategies.

Main Results:

  • Disease-modifying therapies are crucial but insufficient for optimal patient outcomes.
  • Multidisciplinary management significantly improves quality of life and functional capabilities in MS patients.
  • A coordinated approach enhances patient adherence and overall well-being.

Conclusions:

  • Optimal management of multiple sclerosis necessitates a dual focus on disease modification and comprehensive, multidisciplinary care.
  • Integrating specialized therapies with a focus on functional capabilities and quality of life is paramount for improving patient outcomes in multiple sclerosis.